Cevec Pharmaceuticals and Aragen Bioscience Sign License Agreement

Cevec Pharmaceuticals and Aragen Bioscience have announced the signing of a strategic license agreement. This license enables the latter to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.

The transient CAP-T protein production technology is based on CAP cells, an immortalized cell line for stable protein production developed by the former.

These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.